{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:00:38Z","timestamp":1761894038119,"version":"3.32.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.jbspin.2004.09.003","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T01:17:40Z","timestamp":1103159860000},"page":"330-334","source":"Crossref","is-referenced-by-count":17,"title":["Severe pyogenic infections in patients taking infliximab"],"prefix":"10.1016","volume":"72","author":[{"given":"H\u00e9l\u00e8ne","family":"Maillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ornetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Grimault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Ramon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie Melac","family":"Ducamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Saidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Francis","family":"Maillefert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl I","key":"10.1016\/j.jbspin.2004.09.003_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.58.2008.i61","article-title":"Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF\u03b1 treatment","volume":"58","author":"Harriman","year":"1999","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 3","key":"10.1016\/j.jbspin.2004.09.003_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.60.90003.iii51","article-title":"\u201cStepping-up\u201d from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate","volume":"60","author":"Hochberg","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2004.09.003_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 28","key":"10.1016\/j.jbspin.2004.09.003_bib4","first-page":"S106","article-title":"Infliximab in the treatment of active and severe ankylosing spondylitis","volume":"20","author":"Brandt","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2004.09.003_bib5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis. Rheum."},{"issue":"Suppl 28","key":"10.1016\/j.jbspin.2004.09.003_bib6","first-page":"S126","article-title":"Anti-tumour necrosis factor (TNF)-\u03b1 therapy in undifferentiated spondyloarthropathy","volume":"20","author":"Schnarr","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2004.09.003_bib7","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014258","article-title":"Infliximab therapy in patients with ankylosing spondylitis: an open label 12\u00a0month study","volume":"62","author":"Temekonidis","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2004.09.003_bib8","first-page":"610","article-title":"Traitement de maladies inflammatoires\u00a0: s\u00e9curit\u00e9 d\u2019emploi \u00e0 long terme de l\u2019infliximab","volume":"30","author":"Schaible","year":"2001","journal-title":"Press. Med."},{"key":"10.1016\/j.jbspin.2004.09.003_bib9","first-page":"667","article-title":"Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis","volume":"29","author":"Shergy","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2004.09.003_bib10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(02)07718-8","article-title":"Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis","volume":"359","author":"Day","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 65","key":"10.1016\/j.jbspin.2004.09.003_bib11","first-page":"33","article-title":"What are the risks of biologic therapy in rheumatoid arthritis? An update on safety","volume":"29","author":"Weisman","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2004.09.003_bib12","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicentre-active surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2004.09.003_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0248-8663(01)00556-2","article-title":"Anticorps anti-TNF \u03b1 (infliximab) et tuberculose: \u00e0 propos de trois cas","volume":"23","author":"Roth","year":"2002","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.jbspin.2004.09.003_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1297-319X(02)00387-1","article-title":"Recommendations about the prevention and management of tuberculosis in patients taking infliximab","volume":"69","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2004.09.003_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/ard.61.7.653","article-title":"Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis","volume":"6","author":"Harney","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2004.09.003_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2004.09.003_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard.62.1.81","article-title":"Severe septicaemia in a patient with polychondritis and Sweet\u2019s syndrome after initiation of treatment with infliximab","volume":"62","author":"Matzkies","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2004.09.003_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/ard.2003.006270","article-title":"Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondylarthritis","volume":"63","author":"Olivieri","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2004.09.003_bib19","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti-tumor necrosis factor alpha therapy","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis. Rheum."},{"issue":"Suppl 2","key":"10.1016\/j.jbspin.2004.09.003_bib20","first-page":"2","article-title":"Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)","volume":"62","author":"Furst","year":"2003","journal-title":"Ann. Rheum. Dis."},{"unstructured":"British Society for Rheumatology. Guidelines for prescribing TNF-\u03b1 blockers in adults with rheumatoid arthritis: report of a working party of the British Society for Rheumatology. Available from: https:\/\/www.msecportal.org\/portal\/editorial\/PublicPages\/bsr\/536883013\/1.doc.","key":"10.1016\/j.jbspin.2004.09.003_bib21"},{"key":"10.1016\/j.jbspin.2004.09.003_bib22","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2004.09.003_bib23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2004.09.003_bib24","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis. Rheum."},{"key":"10.1016\/j.jbspin.2004.09.003_bib25","first-page":"2525","article-title":"The use of infliximab in academic rheumatology practice: an audit of early clinical experience","volume":"29","author":"Fitzcharles","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2004.09.003_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.jbspin.2004.09.003_bib27","first-page":"30","article-title":"Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis","volume":"62","author":"Flendrie","year":"2003","journal-title":"Ann. Rheum. Dis."},{"unstructured":"Update of BSR guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis. https:\/\/www.msecportal.org\/portal\/editorial\/PublicPages\/bsr\/536883013\/FinalTNFforRAguideline.pdf.","key":"10.1016\/j.jbspin.2004.09.003_bib28"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X04001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X04001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T11:17:07Z","timestamp":1734779827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X04001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S1297319X04001903"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2004.09.003","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}